pharma news, views and analysis - pharmaphorum.com

Trending

in News
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
May 30, 2020 Share
X
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
https://pharmaphorum.com/news/asco-2020-astrazeneca-enhertu-cancer/
in News
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trials
May 30, 2020 Share
X
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trials
https://pharmaphorum.com/news/bcma-jnj-bms-myeloma-trials/

Latest News

Given after surgery, AZ’s Tagrisso prevents lung cancer coming back

Given after surgery, AZ’s Tagrisso prevents lung cancer coming back

AstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of

X

Given after surgery, AZ’s Tagrisso prevents lung cancer coming back

https://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/

Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancer

Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancer

Merck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations,

X

Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancer

https://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/

Roche signs up with Oncimmune to explore immunotherapy responses

Roche signs up with Oncimmune to explore immunotherapy responses

Roche has doubled down on a partnership with UK biotech Oncimmune looking at how autoantibodies can affect patients’

X

Roche signs up with Oncimmune to explore immunotherapy responses

https://pharmaphorum.com/news/roche-signs-up-with-oncimmune-to-explore-immunotherapy-responses/

Views & analysis

ASCO 2020 virtual annual meeting – day 1

ASCO 2020 virtual annual meeting – day 1

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO)

X

ASCO 2020 virtual annual meeting – day 1

https://pharmaphorum.com/oncology/asco-2020-virtual-meeting-day-1/

ASCO 2020 virtual annual meeting – day 2

ASCO 2020 virtual annual meeting – day 2

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO)

X

ASCO 2020 virtual annual meeting – day 2

https://pharmaphorum.com/oncology/asco-2020-virtual-meeting-day-2/

Secondary effects of COVID-19 on pharma, healthcare and patients

Secondary effects of COVID-19 on pharma, healthcare and patients

Reminders of the impact of the COVID-19 pandemic on our healthcare system, economy, and day-to-day lives are everywhere.

X

Secondary effects of COVID-19 on pharma, healthcare and patients

https://pharmaphorum.com/views-analysis-digital/secondary-effects-of-covid-19-on-pharma-healthcare-and-patients/

Debates & Insights

Cost & Management of Oncology Combination Regimens

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

X

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

X

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

X

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

Partner Content

Q&A with SKAN AG speaker released for HPAPI 2020

Q&A with SKAN AG speaker released for HPAPI 2020

HPAPI Speaker Interview

X

Q&A with SKAN AG speaker released for HPAPI 2020

https://pharmaphorum.com/partner-content/qa-with-skan-ag-speaker-released-forhpapi-2020/

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

RNA Therapeutics

X

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/attendee-list-released-for-smis-9th-annual-rna-therapeutics/

RNA Therapeutics conference will take place in just 4 weeks!

RNA Therapeutics conference will take place in just 4 weeks!

4 Weeks Until RNA Therapeutics

X

RNA Therapeutics conference will take place in just 4 weeks!

https://pharmaphorum.com/partner-content-oncology/rna-therapeutics-conference-will-take-place-in-just-4-weeks/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com